Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo11C-BU99008 PET study.

Wilson H, Dervenoulas G, Pagano G, Tyacke RJ, Polychronis S, Myers J, Gunn RN, Rabiner EA, Nutt D, Politis M.

Brain. 2019 Aug 26. pii: awz260. doi: 10.1093/brain/awz260. [Epub ahead of print]

PMID:
31504212
2.

In vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury.

Gorgoraptis N, Li LM, Whittington A, Zimmerman KA, Maclean LM, McLeod C, Ross E, Heslegrave A, Zetterberg H, Passchier J, Matthews PM, Gunn RN, McMillan TM, Sharp DJ.

Sci Transl Med. 2019 Sep 4;11(508). pii: eaaw1993. doi: 10.1126/scitranslmed.aaw1993.

PMID:
31484787
3.

Dopamine D2/D3 receptor abnormalities after traumatic brain injury and their relationship to post-traumatic depression.

Jolly AE, Raymont V, Cole JH, Whittington A, Scott G, De Simoni S, Searle G, Gunn RN, Sharp DJ.

Neuroimage Clin. 2019 Jul 22;24:101950. doi: 10.1016/j.nicl.2019.101950. [Epub ahead of print]

4.

Characterization of 3 PET tracers for Quantification of Mitochondrial and Synaptic function in Healthy Human Brain: 18F-BCPP-EF, 11C-SA-4503, 11C-UCB-J.

Mansur A, Rabiner EA, Comley RA, Lewis Y, Middleton LT, Huiban M, Passchier J, Tsukada H, Gunn RN.

J Nucl Med. 2019 Jul 19. pii: jnumed.119.228080. doi: 10.2967/jnumed.119.228080. [Epub ahead of print]

PMID:
31324712
5.

Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.

Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, Polychronis S, Simitsi A, Giordano B, Chappell Z, Corcoran B, Stamelou M, Gunn RN, Pellecchia MT, Rabiner EA, Barone P, Stefanis L, Politis M.

Lancet Neurol. 2019 Aug;18(8):748-759. doi: 10.1016/S1474-4422(19)30140-1. Epub 2019 Jun 19.

PMID:
31229470
6.

Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease.

Pagano G, Niccolini F, Wilson H, Yousaf T, Khan NL, Martino D, Plisson C, Gunn RN, Rabiner EA, Piccini P, Foltynie T, Politis M.

Mov Disord. 2019 Jun 3. doi: 10.1002/mds.27733. [Epub ahead of print]

PMID:
31158314
7.

Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.

Martín-Bastida A, Lao-Kaim NP, Roussakis AA, Searle GE, Xing Y, Gunn RN, Schwarz ST, Barker RA, Auer DP, Piccini P.

Brain. 2019 Jul 1;142(7):2023-2036. doi: 10.1093/brain/awz120.

PMID:
31056699
8.

The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease.

Wilson H, Pagano G, Niccolini F, Muhlert N, Mehta MA, Searle G, Gunn RN, Rabiner EA, Foltynie T, Politis M.

Parkinsonism Relat Disord. 2019 Feb 22. pii: S1353-8020(19)30073-2. doi: 10.1016/j.parkreldis.2019.02.027. [Epub ahead of print]

PMID:
30824285
9.

Accuracy and reliability of [11C]PBR28 specific binding estimated without the use of a reference region.

Plavén-Sigray P, Schain M, Zanderigo F; Karolinska [(11)C]PBR28 study group, Rabiner EA, Gunn RN, Ogden RT, Cervenka S.

Neuroimage. 2019 Mar;188:102-110. doi: 10.1016/j.neuroimage.2018.11.020. Epub 2018 Nov 27.

10.

PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology.

Niccolini F, Mencacci NE, Yousaf T, Rabiner EA, Salpietro V, Pagano G, Balint B, Efthymiou S, Houlden H, Gunn RN, Wood N, Bhatia KP, Politis M.

Mov Disord. 2018 Dec;33(12):1961-1965. doi: 10.1002/mds.27523. Epub 2018 Oct 21.

PMID:
30345538
11.

Amyloid Load: A More Sensitive Biomarker for Amyloid Imaging.

Whittington A, Gunn RN; Alzheimer’s Disease Neuroimaging Initiative.

J Nucl Med. 2019 Apr;60(4):536-540. doi: 10.2967/jnumed.118.210518. Epub 2018 Sep 6.

12.

Disease-related patterns of in vivo pathology in Corticobasal syndrome.

Niccolini F, Wilson H, Hirschbichler S, Yousaf T, Pagano G, Whittington A, Caminiti SP, Erro R, Holton JL, Jaunmuktane Z, Esposito M, Martino D, Abdul A, Passchier J, Rabiner EA, Gunn RN, Bhatia KP, Politis M; Alzheimer’s Disease Neuroimaging Initiative.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2413-2425. doi: 10.1007/s00259-018-4104-2. Epub 2018 Aug 8.

13.

First evaluation of PET-based human biodistribution and radiation dosimetry of 11C-BU99008, a tracer for imaging the imidazoline2 binding site.

Venkataraman AV, Keat N, Myers JF, Turton S, Mick I, Gunn RN, Rabiner EA, Passchier J, Parker CA, Tyacke RJ, Nutt DJ.

EJNMMI Res. 2018 Jul 30;8(1):71. doi: 10.1186/s13550-018-0429-x.

14.

Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals.

Turton S, Myers JF, Mick I, Colasanti A, Venkataraman A, Durant C, Waldman A, Brailsford A, Parkin MC, Dawe G, Rabiner EA, Gunn RN, Lightman SL, Nutt DJ, Lingford-Hughes A.

Mol Psychiatry. 2018 Jun 25. doi: 10.1038/s41380-018-0107-4. [Epub ahead of print]

15.

Building a database for brain 18 kDa translocator protein imaged using [11C]PBR28 in healthy subjects.

Paul S, Gallagher E, Liow JS, Mabins S, Henry K, Zoghbi SS, Gunn RN, Kreisl WC, Richards EM, Zanotti-Fregonara P, Morse CL, Hong J, Kowalski A, Pike VW, Innis RB, Fujita M.

J Cereb Blood Flow Metab. 2019 Jun;39(6):1138-1147. doi: 10.1177/0271678X18771250. Epub 2018 May 11.

PMID:
29749279
16.

Gait in Mild Alzheimer's Disease: Feasibility of Multi-Center Measurement in the Clinic and Home with Body-Worn Sensors: A Pilot Study.

Mc Ardle R, Morris R, Hickey A, Del Din S, Koychev I, Gunn RN, Lawson J, Zamboni G, Ridha B, Sahakian BJ, Rowe JB, Thomas A, Zetterberg H, MacKay C, Lovestone S, Rochesteron L; Deep and Frequent Phenotyping study team (.

J Alzheimers Dis. 2018;63(1):331-341. doi: 10.3233/JAD-171116. Erratum in: J Alzheimers Dis. 2018;63(4):1557.

PMID:
29614664
17.

Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 Binding Site in Human Brain.

Tyacke RJ, Myers JFM, Venkataraman A, Mick I, Turton S, Passchier J, Husbands SM, Rabiner EA, Gunn RN, Murphy PS, Parker CA, Nutt DJ.

J Nucl Med. 2018 Oct;59(10):1597-1602. doi: 10.2967/jnumed.118.208009. Epub 2018 Mar 9.

18.

Imaging Aβ and tau in early stage Alzheimer's disease with [18F]AV45 and [18F]AV1451.

Firouzian A, Whittington A, Searle GE, Koychev I, Zamboni G, Lovestone S, Gunn RN; Deep and Frequent Phenotyping study team.

EJNMMI Res. 2018 Mar 2;8(1):19. doi: 10.1186/s13550-018-0371-y.

19.

Translocator Protein as an Imaging Marker of Macrophage and Stromal Activation in Rheumatoid Arthritis Pannus.

Narayan N, Owen DR, Mandhair H, Smyth E, Carlucci F, Saleem A, Gunn RN, Rabiner EA, Wells L, Dakin SG, Sabokbar A, Taylor PC.

J Nucl Med. 2018 Jul;59(7):1125-1132. doi: 10.2967/jnumed.117.202200. Epub 2018 Jan 4.

20.

Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration.

Scott G, Zetterberg H, Jolly A, Cole JH, De Simoni S, Jenkins PO, Feeney C, Owen DR, Lingford-Hughes A, Howes O, Patel MC, Goldstone AP, Gunn RN, Blennow K, Matthews PM, Sharp DJ.

Brain. 2018 Feb 1;141(2):459-471. doi: 10.1093/brain/awx339.

21.

Spatiotemporal Distribution of β-Amyloid in Alzheimer Disease Is the Result of Heterogeneous Regional Carrying Capacities.

Whittington A, Sharp DJ, Gunn RN; Alzheimer’s Disease Neuroimaging Initiative.

J Nucl Med. 2018 May;59(5):822-827. doi: 10.2967/jnumed.117.194720. Epub 2017 Nov 16.

22.

Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis.

Datta G, Colasanti A, Rabiner EA, Gunn RN, Malik O, Ciccarelli O, Nicholas R, Van Vlierberghe E, Van Hecke W, Searle G, Santos-Ribeiro A, Matthews PM.

Brain. 2017 Nov 1;140(11):2927-2938. doi: 10.1093/brain/awx228.

23.

Comparison of four 11C-labeled PET ligands to quantify translocator protein 18 kDa (TSPO) in human brain: (R)-PK11195, PBR28, DPA-713, and ER176-based on recent publications that measured specific-to-non-displaceable ratios.

Fujita M, Kobayashi M, Ikawa M, Gunn RN, Rabiner EA, Owen DR, Zoghbi SS, Haskali MB, Telu S, Pike VW, Innis RB.

EJNMMI Res. 2017 Oct 16;7(1):84. doi: 10.1186/s13550-017-0334-8.

24.

PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers.

Koychev I, Gunn RN, Firouzian A, Lawson J, Zamboni G, Ridha B, Sahakian BJ, Rowe JB, Thomas A, Rochester L, Ffytche D, Howard R, Zetterberg H, MacKay C, Lovestone S; Deep and Frequent Phenotyping study team (.

J Alzheimers Dis. 2017;60(1):283-293. doi: 10.3233/JAD-170129. Erratum in: J Alzheimers Dis. 2018;63(1):407.

25.

Quantification of human brain PDE4 occupancy by GSK356278: A [11C](R)-rolipram PET study.

van der Aart J, Salinas C, Dimber R, Pampols-Maso S, Weekes AA, Tonkyn J, Gray FA, Passchier J, Gunn RN, Rabiner EA.

J Cereb Blood Flow Metab. 2018 Nov;38(11):2033-2040. doi: 10.1177/0271678X17720868. Epub 2017 Jul 24.

26.

Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits.

Niccolini F, Wilson H, Pagano G, Coello C, Mehta MA, Searle GE, Gunn RN, Rabiner EA, Foltynie T, Politis M.

Neurology. 2017 Aug 8;89(6):586-593. doi: 10.1212/WNL.0000000000004201. Epub 2017 Jul 12.

PMID:
28701494
27.

Quantitative analysis of dynamic 18F-FDG PET/CT for measurement of lung inflammation.

Coello C, Fisk M, Mohan D, Wilson FJ, Brown AP, Polkey MI, Wilkinson I, Tal-Singer R, Murphy PS, Cheriyan J, Gunn RN.

EJNMMI Res. 2017 Dec;7(1):47. doi: 10.1186/s13550-017-0291-2. Epub 2017 May 25.

28.

11C-DPA-713 has much greater specific binding to translocator protein 18 kDa (TSPO) in human brain than 11C-( R)-PK11195.

Kobayashi M, Jiang T, Telu S, Zoghbi SS, Gunn RN, Rabiner EA, Owen DR, Guo Q, Pike VW, Innis RB, Fujita M.

J Cereb Blood Flow Metab. 2018 Mar;38(3):393-403. doi: 10.1177/0271678X17699223. Epub 2017 Mar 21.

29.

11C-PBR28 and 18F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis.

Datta G, Colasanti A, Kalk N, Owen D, Scott G, Rabiner EA, Gunn RN, Lingford-Hughes A, Malik O, Ciccarelli O, Nicholas R, Nei L, Battaglini M, Stefano ND, Matthews PM.

J Nucl Med. 2017 Sep;58(9):1477-1482. doi: 10.2967/jnumed.116.187161. Epub 2017 Mar 16.

30.

Quantification of Lung PET Images: Challenges and Opportunities.

Chen DL, Cheriyan J, Chilvers ER, Choudhury G, Coello C, Connell M, Fisk M, Groves AM, Gunn RN, Holman BF, Hutton BF, Lee S, MacNee W, Mohan D, Parr D, Subramanian D, Tal-Singer R, Thielemans K, van Beek EJ, Vass L, Wellen JW, Wilkinson I, Wilson FJ.

J Nucl Med. 2017 Feb;58(2):201-207. doi: 10.2967/jnumed.116.184796. Epub 2017 Jan 12. Review.

31.

Imaging in Central Nervous System Drug Discovery.

Gunn RN, Rabiner EA.

Semin Nucl Med. 2017 Jan;47(1):89-98. doi: 10.1053/j.semnuclmed.2016.09.001. Epub 2016 Oct 28. Review.

32.

Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis.

Datta G, Violante IR, Scott G, Zimmerman K, Santos-Ribeiro A, Rabiner EA, Gunn RN, Malik O, Ciccarelli O, Nicholas R, Matthews PM.

Mult Scler. 2017 Oct;23(11):1469-1478. doi: 10.1177/1352458516681504. Epub 2016 Dec 7.

33.

Role of 18F-fluorodeoxyglucose Positron Emission Tomography in the Monitoring of Inflammatory Activity in Crohn's Disease.

Russo EA, Khan S, Janisch R, Gunn RN, Rabiner EA, Taylor SA, Matthews PM, Orchard TR.

Inflamm Bowel Dis. 2016 Nov;22(11):2619-2629.

PMID:
27753695
34.

Evidence for GABA-A receptor dysregulation in gambling disorder: correlation with impulsivity.

Mick I, Ramos AC, Myers J, Stokes PR, Chandrasekera S, Erritzoe D, Mendez MA, Gunn RN, Rabiner EA, Searle GE, Galduróz JCF, Waldman AD, Bowden-Jones H, Clark L, Nutt DJ, Lingford-Hughes AR.

Addict Biol. 2017 Nov;22(6):1601-1609. doi: 10.1111/adb.12457. Epub 2016 Oct 13.

35.

Evidence of Brain Inflammation in Patients with Human T-Lymphotropic Virus Type 1-Associated Myelopathy (HAM): A Pilot, Multimodal Imaging Study Using 11C-PBR28 PET, MR T1-Weighted, and Diffusion-Weighted Imaging.

Dimber R, Guo Q, Bishop C, Adonis A, Buckley A, Kocsis A, Owen D, Kalk N, Newbould R, Gunn RN, Rabiner EA, Taylor GP.

J Nucl Med. 2016 Dec;57(12):1905-1912. Epub 2016 Aug 25.

36.

Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers.

Wilson H, Niccolini F, Haider S, Marques TR, Pagano G, Coello C, Natesan S, Kapur S, Rabiner EA, Gunn RN, Tabrizi SJ, Politis M.

J Neurol Sci. 2016 Sep 15;368:243-8. doi: 10.1016/j.jns.2016.07.033. Epub 2016 Jul 15.

PMID:
27538642
37.

Quantification of [11C]Ro15-4513 GABAAα5 specific binding and regional selectivity in humans.

Myers JF, Comley RA, Gunn RN.

J Cereb Blood Flow Metab. 2017 Jun;37(6):2137-2148. doi: 10.1177/0271678X16661339. Epub 2016 Jan 1.

38.

Kinetic analysis of the translocator protein positron emission tomography ligand [18F]GE-180 in the human brain.

Feeney C, Scott G, Raffel J, Roberts S, Coello C, Jolly A, Searle G, Goldstone AP, Brooks DJ, Nicholas RS, Trigg W, Gunn RN, Sharp DJ.

Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2201-2210. Epub 2016 Jun 28.

39.

Neuroinflammation in treated HIV-positive individuals: A TSPO PET study.

Vera JH, Guo Q, Cole JH, Boasso A, Greathead L, Kelleher P, Rabiner EA, Kalk N, Bishop C, Gunn RN, Matthews PM, Winston A.

Neurology. 2016 Apr 12;86(15):1425-1432. doi: 10.1212/WNL.0000000000002485. Epub 2016 Feb 24.

40.

Phosphodiesterase 10A in Schizophrenia: A PET Study Using [(11)C]IMA107.

Marques TR, Natesan S, Niccolini F, Politis M, Gunn RN, Searle GE, Howes O, Rabiner EA, Kapur S.

Am J Psychiatry. 2016 Jul 1;173(7):714-21. doi: 10.1176/appi.ajp.2015.15040518. Epub 2016 Feb 19.

41.

Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis.

Colasanti A, Guo Q, Giannetti P, Wall MB, Newbould RD, Bishop C, Onega M, Nicholas R, Ciccarelli O, Muraro PA, Malik O, Owen DR, Young AH, Gunn RN, Piccini P, Matthews PM, Rabiner EA.

Biol Psychiatry. 2016 Jul 1;80(1):62-72. doi: 10.1016/j.biopsych.2015.11.022. Epub 2015 Dec 5.

42.

Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers.

Mick I, Myers J, Ramos AC, Stokes PR, Erritzoe D, Colasanti A, Gunn RN, Rabiner EA, Searle GE, Waldman AD, Parkin MC, Brailsford AD, Galduróz JC, Bowden-Jones H, Clark L, Nutt DJ, Lingford-Hughes AR.

Neuropsychopharmacology. 2016 Jun;41(7):1742-50. doi: 10.1038/npp.2015.340. Epub 2015 Nov 10.

43.

Repurposing the Microsoft Kinect for Windows v2 for external head motion tracking for brain PET.

Noonan PJ, Howard J, Hallett WA, Gunn RN.

Phys Med Biol. 2015 Nov 21;60(22):8753-66. doi: 10.1088/0031-9155/60/22/8753. Epub 2015 Nov 3.

44.

Quantitative imaging of protein targets in the human brain with PET.

Gunn RN, Slifstein M, Searle GE, Price JC.

Phys Med Biol. 2015 Nov 21;60(22):R363-411. doi: 10.1088/0031-9155/60/22/R363. Epub 2015 Oct 29.

45.

Impact of image-based motion correction on dopamine D3/D2 receptor occupancy-comparison of groupwise and frame-by-frame registration approaches.

Jiao J, Searle GE, Schnabel JA, Gunn RN.

EJNMMI Phys. 2015 Dec;2(1):15. doi: 10.1186/s40658-015-0117-0. Epub 2015 Jul 29.

46.

Glucagon increases energy expenditure independently of brown adipose tissue activation in humans.

Salem V, Izzi-Engbeaya C, Coello C, Thomas DB, Chambers ES, Comninos AN, Buckley A, Win Z, Al-Nahhas A, Rabiner EA, Gunn RN, Budge H, Symonds ME, Bloom SR, Tan TM, Dhillo WS.

Diabetes Obes Metab. 2016 Jan;18(1):72-81. doi: 10.1111/dom.12585. Epub 2015 Nov 20.

47.

Human Kinetic Modeling of the 5HT6 PET Radioligand 11C-GSK215083 and Its Utility for Determining Occupancy at Both 5HT6 and 5HT2A Receptors by SB742457 as a Potential Therapeutic Mechanism of Action in Alzheimer Disease.

Parker CA, Rabiner EA, Gunn RN, Searle G, Martarello L, Comley RA, Davy M, Wilson AA, Houle S, Mizrahi R, Laruelle M, Cunningham VJ.

J Nucl Med. 2015 Dec;56(12):1901-9. doi: 10.2967/jnumed.115.162743. Epub 2015 Sep 17.

48.

Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease.

Niccolini F, Foltynie T, Reis Marques T, Muhlert N, Tziortzi AC, Searle GE, Natesan S, Kapur S, Rabiner EA, Gunn RN, Piccini P, Politis M.

Brain. 2015 Oct;138(Pt 10):3003-15. doi: 10.1093/brain/awv219. Epub 2015 Jul 25.

49.

Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.

Niccolini F, Haider S, Reis Marques T, Muhlert N, Tziortzi AC, Searle GE, Natesan S, Piccini P, Kapur S, Rabiner EA, Gunn RN, Tabrizi SJ, Politis M.

Brain. 2015 Oct;138(Pt 10):3016-29. doi: 10.1093/brain/awv214. Epub 2015 Jul 21.

50.

An evaluation of the brain distribution of [(11)C]GSK1034702, a muscarinic-1 (M 1) positive allosteric modulator in the living human brain using positron emission tomography.

Ridler K, Cunningham V, Huiban M, Martarello L, Pampols-Maso S, Passchier J, Gunn RN, Searle G, Abi-Dargham A, Slifstein M, Watson J, Laruelle M, Rabiner EA.

EJNMMI Res. 2014 Dec;4(1):66. doi: 10.1186/s13550-014-0066-y. Epub 2014 Dec 5.

Supplemental Content

Support Center